Lilly's Olumiant delivers positive Phase 2 lupus data

Eli Lilly's recently approved therapy Olumiant improved systemic lupus erythematosus (SLE) compared to placebo in a global Phase 2 study presented at the this year's Annual European Congress of Rheumatology, or EULAR, in the Netherlands.

Study participants taking the higher 4 mg dose of Olumiant had significant resolution of arthritis or rash versus those in the control group, thereby meeting the primary endpoint.

Patients on that higher dose also had greater scores in two measures of disease severity, the Systemic Lupus Erythematosus Responder Index and the Lupus Low Disease Activity State (LLDAS), as well as better flare reduction and lower tender joint counts.

For full story please click here.